open access

Vol 71, No 4 (2020)
Original paper
Published online: 2020-05-15
Submitted: 2020-02-14
Accepted: 2020-04-15
Get Citation

Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome

Erhan Onalan, Burkay Yakar, Abdullah Onder Barım, Mehmet Ferit Gursu
DOI: 10.5603/EP.a2020.0024
·
Pubmed: 32716043
·
Endokrynologia Polska 2020;71(4):319-324.

open access

Vol 71, No 4 (2020)
Original Paper
Published online: 2020-05-15
Submitted: 2020-02-14
Accepted: 2020-04-15

Abstract

Introduction: The aim of this study was to investigate serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes and metabolic syndrome.

Material and methods: The study comprised 18 patients with type 2 diabetes mellitus (T2DM) (nine females, nine males), 18 patients with impaired fasting glucose (IFG) (nine females, nine males), 18 patients with impaired glucose tolerance (IGT) (nine females, nine males), 18 patients with metabolic syndrome (MeS) (nine females, nine males), and 16 healthy individuals (eight females, eight males); serum adiponectin, apelin, resistin levels, fasting and postprandial blood glucose, insulin resistance markers, and lipid parameters were measured.

Results: In the study, serum apelin levels were determined to be significantly lower in IGT, MeS, and T2DM groups compared with the control group (p = 0.002, p = 0.006, and p < 0.001, respectively). Serum resistin levels were determined to be significantly higher in IGT and T2DM groups compared with the control group (p < 0.001 and p < 0.001, respectively).

Conclusions: Apelin and resistin are thought to affect glucose metabolism and insulin resistance. Apelin is an important indicator in individuals with IGT in the prediabetic period and may play a role in preventing diabetic complications and treatment of T2DM.

Abstract

Introduction: The aim of this study was to investigate serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes and metabolic syndrome.

Material and methods: The study comprised 18 patients with type 2 diabetes mellitus (T2DM) (nine females, nine males), 18 patients with impaired fasting glucose (IFG) (nine females, nine males), 18 patients with impaired glucose tolerance (IGT) (nine females, nine males), 18 patients with metabolic syndrome (MeS) (nine females, nine males), and 16 healthy individuals (eight females, eight males); serum adiponectin, apelin, resistin levels, fasting and postprandial blood glucose, insulin resistance markers, and lipid parameters were measured.

Results: In the study, serum apelin levels were determined to be significantly lower in IGT, MeS, and T2DM groups compared with the control group (p = 0.002, p = 0.006, and p < 0.001, respectively). Serum resistin levels were determined to be significantly higher in IGT and T2DM groups compared with the control group (p < 0.001 and p < 0.001, respectively).

Conclusions: Apelin and resistin are thought to affect glucose metabolism and insulin resistance. Apelin is an important indicator in individuals with IGT in the prediabetic period and may play a role in preventing diabetic complications and treatment of T2DM.

Get Citation

Keywords

metabolic syndrome; pre-diabetes; apelin; resistin

About this article
Title

Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome

Journal

Endokrynologia Polska

Issue

Vol 71, No 4 (2020)

Article type

Original paper

Pages

319-324

Published online

2020-05-15

DOI

10.5603/EP.a2020.0024

Pubmed

32716043

Bibliographic record

Endokrynologia Polska 2020;71(4):319-324.

Keywords

metabolic syndrome
pre-diabetes
apelin
resistin

Authors

Erhan Onalan
Burkay Yakar
Abdullah Onder Barım
Mehmet Ferit Gursu

References (19)
  1. Onat T, Emerk K, Sözmen EY. İnsan Biyokimyası. Palme Yayıncılık, Ankara 2006: 280–285.
  2. Beck-Nielsen H. Clinical disorders of insulin resistance. In: Alberti K, DeFronzo RA, Keen H, Zimmet P. ed. International Textbook of Diabetes Mellitus. John Wiley&Sons, Chichester 1992.
  3. Simonson DC, Rossetti L, Giaccari A. Glucose toxicity. In: Alberti K, DeFronzo RA, Keen H, Zimmet P. ed. International Textbook of Diabetes Mellitus. John Wiley&Sons, Chichester 1992: 635–667.
  4. Yarımay Tevfikoğlu G. Tip 2 Diyabetli Bireylerin Çocuklarında Kan CRP, TNF Alfa, İnterlökin 6 ve Resistin Düzeylerinin İnsülin Direnci ile İlişkisi. Karaelmas Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Uzmanlık Tezi, Zonguldak 2010.
  5. Gürlek A. İnsülin direncinde genetik faktörler. In: Çorakçı A. ed. Klinik Endokrinoloji, Meta Basım, İzmir 2001: 49–53.
  6. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002; 13(1): 18–23.
  7. Berger A. Resistin: a new hormone that links obesity with type 2 diabetes. BMJ. 2001; 322: 193.
  8. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50(9): 1511–1525.
  9. Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004; 89(4): 1844–1848.
  10. Ort T, Arjona AA, MacDougall JR, et al. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology. 2005; 146(5): 2200–2209.
  11. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–312.
  12. Hu H, He Lu, Li L, et al. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016; 119(1-2): 20–27.
  13. Akcılar R, Turgut S. Apelinin Kardiyovasküler Fonksiyonlar Üzerine Etkileri. Tıp Araştırmaları Dergisi. 2015; 13(3).
  14. Gourdy P, Cazals L, Thalamas C, et al. Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic‐euglycaemic clamp. Diabetes Obes Metab. 2017; 20(1): 157–164.
  15. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146(4): 1764–1771.
  16. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005; 107(2): 198–211.
  17. Małyszko J, Małyszko JS, Koźminski P, et al. Apelin and cardiac function in hemodialyzed patients: possible relations? Am J Nephrol. 2006; 26(2): 121–126.
  18. Yue P, Jin H, Aillaud M, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298(1): E59–E67.
  19. Zhang Yu, Shen C, Li X, et al. Low plasma apelin in newly diagnosed type 2 diabetes in Chinese people. Diabetes Care. 2009; 32(12): e150.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl